Half-year report · HY
4626.TEDINET S100WYNG
Period2025-04-01 → 2025-09-30
Filed2025-11-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥67.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥119.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥59.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥15.2bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥12.4bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥15.1bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥21.6bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.4bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥15.2bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥12.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.0bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥10.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11.0bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥9.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥191.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥192.0bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥206.8bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥84.6bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥89.0bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥107.0bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥103.0bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥106.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥39.3bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥38.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥57.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥11.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥12.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥8.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥14.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥29.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥11.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥198.36 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥193.18 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥164.52 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 55.9% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥3.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥189m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥18m |
| Electronics Materialsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥46.3bn |
| Electronics Materialsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥46.3bn |
| Electronics Materialsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥13.8bn |
| Medical And Pharmaceuticalsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥18.5bn |
| Medical And Pharmaceuticalsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥18.5bn |
| Medical And Pharmaceuticalsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2.4bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥64.8bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥64.8bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥16.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥68.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥67.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥189m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥16.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥2.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥195m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥138m |
| Electronics Materialsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥42.6bn |
| Electronics Materialsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥42.6bn |
| Electronics Materialsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.0bn |
| Medical And Pharmaceuticalsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| Medical And Pharmaceuticalsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| Medical And Pharmaceuticalsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥931m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥57.6bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥57.6bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥13.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥60.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥59.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥195m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥13.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 512
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision of allowance for doubtful accounts sga | Prior1InterimDuration | -32000000 | JPY |
| Provision of allowance for doubtful accounts sga | InterimDuration | -23000000 | JPY |
| Research and development expenses sga | Prior1InterimDuration | 3296000000 | JPY |
| Research and development expenses sga | InterimDuration | 3653000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00913-000ElectronicsMaterialsReportableSegmentsMember | 42567000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | 15078000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 57645000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2254000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 59899000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00913-000ElectronicsMaterialsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 195000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 195000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00913-000ElectronicsMaterialsReportableSegmentsMember | 42567000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | 15078000000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 57645000000 | JPY |
| Net sales | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2449000000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 60095000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00913-000ElectronicsMaterialsReportableSegmentsMember | 12045000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | 931000000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 12976000000 | JPY |
| Operating income | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 138000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 13115000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00913-000ElectronicsMaterialsReportableSegmentsMember | 46346000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | 18451000000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 64798000000 | JPY |
| Revenues from external customers | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3031000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 67830000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00913-000ElectronicsMaterialsReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 189000000 | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 189000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00913-000ElectronicsMaterialsReportableSegmentsMember | 46346000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | 18451000000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 64798000000 | JPY |
| Net sales | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3221000000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 68019000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00913-000ElectronicsMaterialsReportableSegmentsMember | 13794000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | 2426000000 | JPY |
| Operating income | InterimDuration_ReportableSegmentsMember | 16221000000 | JPY |
| Operating income | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 18000000 | JPY |
| Operating income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 16239000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-06 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第80期（2026年3月期）中（自 2025年4月1日 至 2025年9月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)太陽ホールディングス株式会社 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |